Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.79 |
| ▸ | HTR1A | P08908 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 1/20 | 0.60 |
| ▸ | HTR1D | P28221 | 3/20 | 0.56 |
| ▸ | HTR1B | P28222 | 3/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26509026 | 0.97 | HTR2A (0.81) | HTR2AHTR1AMEN1KMT2AHTR6 | |
| SCHEMBL24723815 | 0.90 | HTR2A (0.97) | HTR2AHTR1AHTR6HTR1DHTR1B | |
| SCHEMBL32669310 | 0.88 | HTR2A (1.00) | HTR2AHTR1AHTR6HTR1DHTR1B | |
| SCHEMBL25249411 | 0.87 | HTR2A (1.00) | HTR2AHTR1AHTR6HTR1DHTR1B | |
| SCHEMBL32669432 | 0.87 | HTR2A (0.63) | HTR2AHTR1AMEN1KMT2AHTR6 | |
| SCHEMBL27085249 | 0.85 | HTR2A (0.59) | HTR2AHTR1AHTR1DHTR1BMPO | |
| SCHEMBL26509036 | 0.83 | HTR2A (0.60) | HTR2AHTR1AHTR1DHTR1BMPO | |
| SCHEMBL27084896 | 0.82 | HTR2A (0.56) | HTR2AHTR1AHTR1DHTR1BMPO | |
| SCHEMBL11534542 | 0.82 | RAB9A (0.66) | HTR2AHTR1AMEN1KMT2AHTR6 | |
| SCHEMBL27084757 | 0.82 | HTR2A (0.56) | HTR2AHTR1AHTR6HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | HTR4, OPRM1, HTR7 | HTR2A 12/4885HTR1A 4/4885MEN1 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.